15/09/2026
The next chapter of obesity medicine may not simply be about making GLP-1 drugs stronger. It may be about combining different biological pathways.
One of the most interesting combinations I’m watching is eloraTZP, bringing together eloralintide, a selective amylin-receptor agonist, with tirzepatide and its GIP/GLP-1 activity. Early combination data have generated considerable interest, with approximately 17% mean weight reduction reported at 16 weeks with eloralintide 3 mg + tirzepatide 5 mg, compared with approximately 10% with tirzepatide 5 mg alone. Those numbers are exciting, but this is exactly where we need to separate excitement from evidence because these are early results and longer-term efficacy, tolerability, safety, discontinuation rates and body composition all matter.
The larger Phase 2 dataset should give us a much clearer picture, and I’ll be watching the evidence closely as it develops.
GIP ObesityMedicine ObesityTreatment WeightManagement MetabolicHealth ClinicalResearch WeightLossScience BodyComposition EvidenceBased
MW Mark Woodcock Home Fitness Training
Personal Trainer & Nutrition Coach
Hertfordshire | North London | South Bedfordshire | South Cambridgeshire
I Travel Direct To You! 🚘
www.markwoodcock.co.uk
[email protected]